Davarzani, N., Hewitt, L. C., Hale, M. D., Melotte, V., Nankivell, M., Hutchins, G. G. A., . . . Grabsch, H. I. (2020). Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: Results from the UK MRC OE02 trial. Dis Esophagus.
Citação norma ChicagoDavarzani, Naser, et al. "Histological Intratumoral Heterogeneity in Pretreatment Esophageal Cancer Biopsies Predicts Survival Benefit From Neoadjuvant Chemotherapy: Results From the UK MRC OE02 Trial." Dis Esophagus 2020.
Citação norma MLADavarzani, Naser, et al. "Histological Intratumoral Heterogeneity in Pretreatment Esophageal Cancer Biopsies Predicts Survival Benefit From Neoadjuvant Chemotherapy: Results From the UK MRC OE02 Trial." Dis Esophagus 2020.